Workflow
Biopharmaceutical research and development
icon
搜索文档
Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders
Globenewswire· 2025-05-02 13:00
Allschwil, Switzerland – May 2, 2025Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Annual Report of the year ending December 31, 2024, will be held on Wednesday, May 28, 2025, at 09.00 CEST at the Congress Center, Messe Basel, Switzerland. Jean-Paul Clozel, Chairman of the Board of Idorsia, commented:“The team at Idorsia continues to go the extra mile to secure the company’s futu ...
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
Newsfilter· 2025-04-25 04:01
文章核心观点 Kiniksa Pharmaceuticals International将在2025年4月29日上午8:30举办电话会议和网络直播,汇报2025年第一季度财务结果和近期投资组合执行情况 [1] 会议信息 - 网络直播可通过公司网站投资者与媒体板块访问 [2] - 电话参会者需注册,注册后会收到确认邮件,包含拨入号码、密码和注册ID [2] - 活动结束约48小时后,公司网站将提供活动回放 [2] 公司介绍 - 公司是一家生物制药公司,致力于为患有使人衰弱疾病的患者改善生活,专注于心血管疾病,通过发现、获取、开发和商业化满足未满足需求的新疗法 [3] - 公司资产组合基于强大生物学原理或已验证机制,有差异化潜力 [3] 联系方式 - 投资者联系人为Jonathan Kirshenbaum,电话(781) 829-3949,邮箱jkirshenbaum@kiniksa.com [4] - 媒体联系人为Tyler Gagnon,电话(781) 431-9100,邮箱tgagnon@kiniksa.com [4]